• Cefiderocol Activity vs. Drug-Resistant Pseudomonas and Acin

  2026-05-01

  This study rigorously compared the in vitro activity of cefiderocol to multiple β-lactam/β-lactamase inhibitor combinations against European Pseudomonas aeruginosa and Acinetobacter spp., including highly resistant clinical isolates. Its findings clarify cefiderocol's therapeutic potential for infections where carbapenem and common β-lactamase inhibitor options fail.

• Digoxin’s Translational Edge: Beyond Cardiac to Antiviral Fr

  2026-04-30

  This thought-leadership article guides translational researchers through the mechanistic foundations and strategic deployment of Digoxin as a Na+/K+ ATPase pump inhibitor, with a dual focus on cardiac and antiviral research. Drawing on recent pharmacokinetic insights, competitive benchmarking, and protocol guidance, it offers actionable recommendations for advancing experimental design beyond traditional paradigms. The piece leverages both the latest peer-reviewed literature and APExBIO’s product rigor, bridging domains and addressing real-world assay challenges.

• Sodium Dicloxacillin Monohydrate: Mechanism and Research Ben

  2026-04-30

  Sodium dicloxacillin monohydrate is a narrow-spectrum β-lactam antibiotic widely employed for research on Gram-positive bacterial infections, notably methicillin-sensitive Staphylococcus aureus (MSSA). This article details its molecular mechanism, in vitro and in vivo efficacy parameters, and critical workflow considerations for scientific use.

• Cefazedone (Refosporen): Applied Workflows & In Vitro Excell

  2026-04-29

  Cefazedone (Refosporen) is a robust, β-lactamase-resistant cephalosporin that excels in in vitro and translational workflows targeting both Gram-positive and Gram-negative pathogens. This article translates recent breakthroughs and validated protocols into actionable guidance for researchers and clinicians, with troubleshooting and protocol optimization tailored to maximize experimental success.

• Meropenem: Ultra-Broad-Spectrum β-Lactam Carbapenem for Rese

  2026-04-29

  Meropenem is an ultra-broad-spectrum β-lactam antibiotic carbapenem with robust efficacy against both Gram-negative and Gram-positive bacteria. Cited as a benchmark antibacterial agent, it is pivotal for resistance modeling and translational research. APExBIO’s Meropenem (SKU A5124) provides high solubility and validated biological activity for advanced laboratory workflows.

• Bafilomycin C1: Strategic V-ATPase Inhibition for Translatio

  2026-04-28

  This thought-leadership article decodes the mechanistic, strategic, and translational impact of Bafilomycin C1—a benchmark vacuolar H+-ATPases inhibitor—on modern disease modeling, high-content phenotypic screening, and de-risking preclinical drug discovery. By synthesizing mechanistic insights, best-practice protocols, and actionable guidance for translational researchers, it illuminates how APExBIO’s Bafilomycin C1 advances autophagy and apoptosis research, bridging the gap between cellular mechanism and clinical relevance.

• MDV3100 (Enzalutamide): Mechanistic Insights for Overcoming

  2026-04-28

  Explore how MDV3100 (Enzalutamide) modulates androgen receptor pathways and informs next-generation strategies to overcome therapeutic resistance in prostate cancer research. This in-depth analysis uniquely integrates glycosaminoglycan biosynthesis, AR signaling inhibition, and practical assay guidance.

• Gamithromycin (ML-1709460): Precision PK/PD Design for Respi

  2026-04-27

  Explore the science behind Gamithromycin (ML-1709460) as a powerful tool for respiratory pathogen research. This article uniquely dissects PK/PD-driven assay design, leveraging advanced findings to guide superior experimental outcomes.

• Vernakalant Hydrochloride for Rapid Cardioversion of AF in t

  2026-04-27

  This article reviews a pivotal post hoc analysis demonstrating that Vernakalant Hydrochloride, a novel atrial-selective antiarrhythmic (RSD1235), rapidly and safely converts recent-onset atrial fibrillation (AF) to sinus rhythm in the emergency department. The findings highlight significant efficacy, a favorable safety profile, and mechanistic selectivity, offering new options for acute AF management.

• Gene Expression Signatures Predict Olaparib Sensitivity in M

  2026-04-26

  Borchert et al. (2019) present a gene expression profiling study revealing that homologous recombination repair (HRR) deficiencies—termed 'BRCAness'—in malignant pleural mesothelioma (MPM) identify tumors susceptible to olaparib treatment. Their findings establish molecular subtypes of MPM with distinct therapeutic vulnerabilities, informing future strategies for personalized cancer chemotherapy research.

• Ceftolozane Sulfate: Decoding PK/PD and Resistance in P. aer

  2026-04-25

  Discover the advanced pharmacokinetic and resistance nuances of Ceftolozane sulfate. This article dissects its bactericidal action against Pseudomonas aeruginosa and translates the latest research into actionable insights for assay design and clinical modeling.

• Ceftolozane-Tazobactam in Nosocomial Pneumonia: Clinical and

  2026-04-24

  This article examines the innovation and clinical impact of ceftolozane-tazobactam for nosocomial pneumonia, as detailed by Candel et al. The study establishes the agent’s robust activity against multidrug-resistant Pseudomonas aeruginosa and select Enterobacteriaceae, and explores its pharmacological, microbiological, and resistance-avoidance properties. Implications for optimizing antibiotic resistance assays and comparative insights with glycopeptide controls such as Vancomycin hydrochloride are discussed.

• In Vitro Activity and Pharmacokinetics of Temafloxacin: Insi

  2026-04-24

  This article reviews a pivotal 1989 study that systematically evaluated temafloxacin’s in vitro antibacterial spectrum, pharmacokinetics, and tissue penetration. The findings highlight its potent activity against diverse pathogens and robust tissue distribution, informing protocols for research on Gram-positive, Gram-negative, and intracellular bacteria.

• Y-27632 ROCK Inhibitor: Protocols and Pitfalls in Cytoskelet

  2026-04-23

  Y-27632 delivers selective, ATP-competitive inhibition of ROCK1/2, enabling precise control of cytoskeletal architecture and stress fiber modulation in cell biology workflows. This guide bridges advanced cancer biology insights with hands-on protocol optimization, highlighting troubleshooting strategies for maximum reproducibility.

• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-04-23

  This study provides a detailed molecular epidemiology of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) from eight hospitals in Guangdong (2022–2024), revealing high prevalence, diverse genetic backgrounds, and efficient gene transfer. These findings inform both surveillance strategies and experimental modeling of multidrug resistance.

456 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page